Osteoporosis management in hematologic stem cell transplant recipients: Executive summary
Date
2021-06
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier GmbH.
Abstract
Background: Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT.
Results: In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture.
Conclusion: This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication.
Description
CITATION: Kendler, D.L. et al. 2021. Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. Journal of Bone Oncology 28(2021):100361.
doi.10.1016/j.jbo.2021.100361
The original publication is available at: elsevier.com
The original publication is available at: elsevier.com
Keywords
Hematopoietic stem cells, Bone marrow -- Transplantation, Stem cells -- Transplantation, Bones -- Diseases, Fractures, UCTD
Citation
Kendler, D.L. et al. 2021. Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. Journal of Bone Oncology 28(2021):100361.
doi.10.1016/j.jbo.2021.100361